Therapeutic Proteins to 2016: Drugs , Devices, Diseases, Markets and Forecasts

DUBLIN, March 22, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Therapeutic Proteins to 2016. Drugs, Devices, Diseases, Markets and Forecasts" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution.

It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration.

These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a significant effect on the way drugs and devices are developed.

Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.

Highlights:

- Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable future protein drug

- Examines protein delivery design issues, packaging, distribution and technology factors

See the original post here:
Therapeutic Proteins to 2016: Drugs , Devices, Diseases, Markets and Forecasts